CLINICAL TRIALS PROFILE FOR POTASSIUM ACETATE

505(b)(2) Clinical Trials for Potassium Acetate

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT04039828 ↗	Zinc Sulfate Acceptability	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	N/A	2019-09-09	Introduction: Zinc (Zn) is an essential mineral widely distributed within the human body with metalloproteins, Zinc-binding proteins, etc. It is necessary for signal transduction and also cell growth and proliferation via respective metallo- and zinc-dependent enzymes. Zinc supplementation can significantly reduce diarrheal severity and duration as well as prevents future incidences and reduces use of other medications in diarrhoea. For this reason WHO, UNICEF, USAID and experts worldwide jointly recommended zinc supplementation (10 mg for infants less than 6 months old and 20 mg in 6 - 59 months old) combined with reduced osmolarity ORS for clinical management of acute diarrhoea. But due to strong metallic taste zinc products are less palatable to children even after using masking flavours as recommended by WHO. Several companies have formulated the product since WHO recommendations came but still transient side effects like vomiting and regurgitation remain evident. Despite careful counselling to the caregivers expected adherence rate to 10 days regimen of zinc supplement is yet to be reached. With the aim to increase zinc supplement coverage during acute diarrheal illness, it is necessary to conduct a study to introduce new formulation Zinc tablet which is more palatable, more dispersible and more acceptable. Intervention: Zinc sulfate [Zinc Dispersible Tablet, 20 mg; (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)] Methods: Prospective, open label, interventional study Hypothesis: Improved formulation of Zinc Sulfate will have good acceptability. Study population: Stratum 1: 3 months -

All Clinical Trials for Potassium Acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00118482 ↗	Clinical Trial for the Prevention of Vasovagal Syncope	Completed	Canadian Institutes of Health Research (CIHR)	Phase 4	2005-05-01	The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
NCT00118482 ↗	Clinical Trial for the Prevention of Vasovagal Syncope	Completed	University of Calgary	Phase 4	2005-05-01	The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	Eli Lilly and Company	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗	Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma	Completed	National University Hospital, Singapore	Phase 2	2000-07-01	Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer

Clinical Trial Conditions for Potassium Acetate

Condition Name

Condition Name for Potassium Acetate
Intervention	Trials
Diabetes	2
Myocardial Failure	1
Syncope, Vasovagal, Neurally-Mediated	1
Diabetic Ketoacidosis	1

Condition MeSH

Condition MeSH for Potassium Acetate
Intervention	Trials
Diarrhea	2
Ketosis	2
Diabetic Ketoacidosis	2
Neoplasm Metastasis	1

Clinical Trial Locations for Potassium Acetate

Trials by Country

Trials by Country for Potassium Acetate
Location	Trials
United States	12
Canada	10
Bangladesh	3
Taiwan	2
Brazil	1

Trials by US State

Trials by US State for Potassium Acetate
Location	Trials
Massachusetts	2
Virginia	2
Tennessee	1
New York	1
Wisconsin	1

Clinical Trial Progress for Potassium Acetate

Clinical Trial Phase

Clinical Trial Phase for Potassium Acetate
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	5
Phase 3	2

Clinical Trial Status

Clinical Trial Status for Potassium Acetate
Clinical Trial Phase	Trials
Completed	10
Recruiting	4
Unknown status	2

Clinical Trial Sponsors for Potassium Acetate

Sponsor Name

Sponsor Name for Potassium Acetate
Sponsor	Trials
International Centre for Diarrhoeal Disease Research, Bangladesh	3
Alphacait, LLC	1
Turku University Hospital	1

Sponsor Type

Sponsor Type for Potassium Acetate
Sponsor	Trials
Other	28
Industry	5
NIH	1

Potassium Acetate: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is the current clinical-trials picture for potassium acetate?

Potassium acetate is an established pharmaceutical-grade ingredient with a long history of medical use, primarily as a potassium source and in specific formulations (notably intravenous infusions used in hospital settings). Public clinical-trials visibility for “potassium acetate” as a standalone drug is typically fragmented across:

• formulation/route variants,
• hospital protocols,
• and regional naming conventions (drug substance vs finished product).

Under a strict “drug-level” lens, the market does not show a consistent, global pipeline of late-stage, randomized pivotal programs for a new “potassium acetate” branded therapeutic. Where clinical activity is visible, it often appears as:

• supportive safety or dosing studies tied to electrolyte management,
• protocol trials in acute care contexts,
• or studies using acetate-buffered potassium salts as comparators.

Market implication: Potassium acetate behaves more like a traded ingredient within hospital supply chains than a late-stage pipeline drug with clear event-driven valuation milestones.

Where does potassium acetate sit in competitive context?

Potassium acetate competes on practical parameters rather than “novel MoA differentiation.” Decision drivers in acute care procurement and formulary control include:

• unit cost per mmol potassium delivered,
• compatibility with IV lines and co-infusions,
• infusion stability and shelf life,
• and the availability of alternative potassium salts (e.g., potassium chloride).

Direct comparator group (same therapeutic intent):

• Potassium chloride (most common alternative)
• Potassium phosphate (select scenarios)
• Magnesium/potassium combination products (where applicable)

Competitive posture:

• If potassium acetate is used because of specific clinical or formulation reasons (acetate metabolism, acid-base handling, local protocol preferences), it can hold formulary position even when unit prices fluctuate.
• If the hospital pathway defaults to potassium chloride, potassium acetate volume is more sensitive to pricing and supply continuity.

What does the market look like today?

Demand drivers

Potassium acetate demand is driven by:

• inpatient electrolyte replacement use,
• critical care protocols (where acetate-buffered solutions are used),
• nephrology and dialysis-adjacent care pathways in select systems,
• and substitution demand when products face shortages or formulary refresh cycles.

Supply and pricing dynamics

Hospital electrolyte markets are typically characterized by:

• procurement-led purchasing with tenders and periodic contracts,
• pricing anchored to finished-product equivalents (not pure chemical commodity),
• and supply constraints that can temporarily shift utilization across potassium salt types.

Regulatory status

Potassium acetate products are generally treated as established drugs/ingredients in multiple jurisdictions, which reduces the likelihood that near-term growth depends on approvals. Growth tends to come from:

• incremental formulary adoption,
• switching within hospital pathways,
• and increased usage intensity during periods of heightened inpatient volume or protocol changes.

How large is the market and what is the likely growth profile?

A precise, defensible market size and forecast for “potassium acetate” alone requires a source that breaks down sales by:

• active substance,
• finished-product concentration (e.g., injection strength),
• and geography with consistent coding (e.g., national drug registries or sales datasets).

No such complete market-sizing dataset is available in the provided material. In the absence of that dataset, a quantitative forecast would not meet a strict “hard data only” standard.

What can be stated with high confidence (structure of projection):

• Base case: volume grows modestly with global hospital activity and electrolyte utilization, but not at pipeline-growth rates.
• Upside: formulary switches toward acetate-buffered potassium salts due to clinical protocol updates, shortage mitigation, or product availability.
• Downside: substitution back to potassium chloride if pricing favors alternatives, or if local procurement policies standardize on one salt.

What clinical endpoints matter most for adoption?

Where new studies do appear, they generally map to decision-grade endpoints:

• correction speed for hypokalemia in defined care settings,
• tolerability and infusion site reactions,
• acid-base and electrolyte stability (especially in renal impairment),
• safety in co-administered fluids and concomitant therapies.

Because potassium acetate is not typically a “new MoA” drug, adoption tends to hinge on practical superiority in specific pathways rather than headline efficacy expansion.

What is the most realistic 3-stage projection framework?

Stage 1: Supply-chain and formulary continuity (0 to 12 months)

• If uninterrupted product supply exists, usage stays aligned with existing protocols.
• Price changes or shortages can shift mix between potassium acetate and alternative potassium salts.

Expected impact: small net change in volume; more variability in mix.

Stage 2: Protocol standardization and hospital contracting (12 to 36 months)

Hospitals re-bid tenders and standardize formularies on periodic cycles. Potassium acetate utilization can rise if:

• it is the tender winner in certain concentrations,
• it remains clinically preferred for acetate-related handling in local protocols,
• or it is bundled into standardized electrolyte replacement kits.

Expected impact: moderate growth if adoption broadens across health systems.

Stage 3: Substitution risk and product lifecycle effects (36 to 60 months)

• As alternative products remain available and price competitive, potassium acetate can lose share.
• If clinical protocol changes favor a different salt or buffering strategy, it can flatten growth.

Expected impact: growth normalizes; upside depends on sustained protocol preference.

Key business implications

For R&D

Potassium acetate is unlikely to be a high-value “new therapeutic” target absent:

• a novel delivery system,
• a differentiated clinical use case with measurable outcomes,
• or a combination strategy that creates clear differentiation.

R&D value is more plausible in:

• formulation improvements (stability, concentration range, infusion compatibility),
• clinical pathway optimization within a defined patient subset,
• and evidence packages targeting formulary decisions.

For investment

The investment thesis, if any, usually tracks:

• contract wins in hospital procurement,
• supply robustness and inventory allocation,
• and pricing spreads versus potassium chloride equivalents.

If a thesis requires “clinical catalyst,” potassium acetate is more likely to deliver it through protocol uptake evidence rather than drug-approval milestones.

Key Takeaways

• Potassium acetate’s clinical-trials profile is primarily supportive and protocol-linked rather than pipeline-driven, which makes “event-catalyst” forecasting weak.
• Competitive dynamics are dominated by hospital procurement and substitution among potassium salts, especially potassium chloride.
• Market growth is structurally tied to inpatient electrolyte utilization and formulary switching, with volatility driven by pricing and supply continuity rather than novel efficacy claims.
• A credible forecast for market size and CAGR requires a dataset that itemizes sales for potassium acetate as a defined active substance and concentration across geographies; absent that, only projection logic by adoption and substitution mechanics can be stated.

FAQs

1. Is potassium acetate a pipeline drug with major upcoming pivotal trials?
   It generally does not present as a globally visible late-stage pipeline drug; usage is typically established and protocol-driven.

2. What most influences hospital use of potassium acetate?
   Tender pricing, supply reliability, and clinical protocol fit versus alternatives like potassium chloride.

3. What clinical outcomes drive formulary adoption?
   Electrolyte correction performance, tolerability, infusion compatibility, and stability in defined patient populations.

4. What is the main substitution risk?
   Hospitals can revert to potassium chloride or other potassium salt options when pricing and procurement policies favor them.

5. How should a market projection be modeled?
   Use a formulary adoption and mix-shift framework tied to procurement cycles and substitution behavior, not a pipeline milestones framework.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (Database). https://clinicaltrials.gov/
[2] World Health Organization. WHO Model Lists of Essential Medicines. (Guidance). https://www.who.int/
[3] U.S. Food and Drug Administration. Drug Safety and Availability / Product Listings. (Resources). https://www.fda.gov/